

**We claim:**

1. A composition comprising a substantially purified thermostable Gux1 peptide, said Gux1 peptide comprising a catalytic domain GH48, a carbohydrate binding domain (CBD) type III, and a carbohydrate binding domain (CBD) type II.
2. The composition of claim 1 wherein the Gux1 peptide is further defined as comprising a linker and a signal peptide.
3. The composition of claim 1 or 2 wherein the GH48 catalytic domain of the Gux1 peptide is further defined as having a length of about 637 to about 643 amino acids.
4. The composition of claim 1, 2, or 3 wherein the carbohydrate binding domain (CBD) type III of the Gux1 peptide is further defined as having a length of about 150 to about 156 amino acids.
5. The composition of claim 1, 2, 3, or 4 wherein the carbohydrate binding domain (CBD) type II of the Gux1 peptide is further defined as having a length of about 95 amino acids to about 105 amino acids in length.
6. The composition of claim 3 wherein the GH48 catalytic domain is further defined as the sequence of SEQ ID NO: 5.
7. The composition of claim 4 wherein the carbohydrate binding domain (CBD) type III is further defined as the sequence of SEQ ID NO: 4.
8. The composition of claim 6 wherein the carbohydrate binding domain (CBD) type II is further defined as the sequence of SEQ ID NO: 7.
9. The composition of claim 1 further defined as comprising a sequence of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 7.
10. A thermal tolerant Gux1 peptide having a sequence of SEQ ID NO: 1.

11. The Gux1 peptide of claim 10 further defined as having a sequence of SEQ ID NO: 2.
12. An industrial mixture suitable for degrading cellulose, such mixture comprising the Gux1  
5 polypeptide of claim 1.
13. The industrial mixture of claim 12 further defined as comprising a detergent.
14. The composition of claim 1 wherein the Gux1 is further defined as comprising a nucleic acid  
10 sequence having at least 90% sequence identity to the nucleic acid sequence encoding an amino acid  
sequence of SEQ ID NO: 5.
15. The composition of claim 1 wherein the Gux1 is further defined as comprising a nucleic acid  
sequence having at least 80% sequence identity to the nucleic acid sequence encoding an amino acid  
sequence of SEQ ID NO: 5.
16. The composition of claim 1 wherein the Gux1 is further defined as comprising a nucleic acid  
sequence having at least 70% sequence identity to the nucleic acid sequence encoding an amino acid  
sequence of SEQ ID NO: 5.
17. The composition of claim 1 wherein the Gux1 is further defined as comprising a nucleic acid  
sequence having at least 90% sequence identity to the nucleic acid sequence encoding the amino  
acid sequence of SEQ ID NO: 7.
18. The composition of claim 1 wherein the Gux1 is further defined as comprising a nucleic acid  
25 sequence having at least 90% sequence identity to the nucleic acid sequence encoding the amino acid  
sequence of SEQ ID NO: 4.
19. The composition of claim 1 wherein the Gux1 is further defined as comprising a nucleic acid  
30 sequence having at least 90% sequence identity to the nucleic acid sequence encoding the amino acid  
sequence of SEQ ID NO: 6.

20. The composition of claim 1 wherein the Gux1 is further defined as comprising a nucleic acid sequence having at least 90% sequence identity to the nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 1.

21. The composition of claim 1 wherein the Gux1 is further defined as comprising a nucleic acid sequence having at least 90% identity to the nucleic acid sequence of SEQ ID NO: 2.

22. The composition of claim 1 wherein the Gux1 is further defined as comprising a nucleic acid sequence encoding a heterologous protein in frame with the Gux1 peptide of claim 1.

23. The composition of claim 22 wherein the heterologous protein in frame with the Gux1 peptide of claim 1 is further defined as a peptide tag.

24. The composition of claim 23 wherein the peptide tag is 6-His, thioredoxin, hemagglutinin, GST, or OmpA signal sequence tag.

24. The composition of claim 22 wherein the heterologous protein is a substrate targeting moiety.

25. The composition of claim 13 wherein the nucleotide sequence encoding the Gux1 is operably linked to a transcriptional or translational regulatory sequence.

26. The composition of claim 25, wherein the transcriptional or translational regulatory sequence comprises a transcriptional promoter or enhancer.

27. An isolated polypeptide molecule comprising:

- a) a sequence of SEQ ID NO: 4;
- b) a sequence of SEQ ID NO: 5;
- c) a sequence of SEQ ID NO: 6;
- d) a sequence of SEQ ID NO: 7;
- e) a sequence of SEQ ID NO: 1; or

f) an amino acid sequence having at least 70% sequence identity with the amino acid sequence of a), b), c), d), or e).

28. The polypeptide molecule of claim 27, having at least 90% sequence identity with the amino acid sequence of a), b), c), d), or e).

29. A fusion protein comprising the polypeptide of claim 27 and a heterologous peptide.

30. The fusion protein of claim 29, wherein the heterologous peptide is a substrate targeting moiety.

31. The fusion protein of claim 29, wherein the heterologous peptide is a peptide tag.

32. The fusion protein of claim 31, wherein the peptide tag is 6-His, thioredoxin, hemagglutinin, GST, or OmpA signal sequence tag.

33. The fusion protein of claim 29, wherein the heterologous peptide is an agent that promotes polypeptide oligomerization.

34. The fusion protein of claim 29, wherein the agent is a leucine zipper.

35. A cellulase-substrate complex comprising the isolated polypeptide molecule of claim 27 bound to cellulose.

36. A vector comprising the polynucleotide molecule that encodes a polypeptide of claim 27.

37. A host cell genetically engineered to express the polypeptide molecule of claim 27.

38. A host cell genetically engineered to express the polynucleotide molecule of claim 27.

39. The host cell of claim 37 or 38, wherein the host cell is a plant cell.

40. The host cell of claim 37 or 38, wherein the host cell is a fungi.
41. The host cell of claim 37 or 38, wherein the host cell is a bacterial cell.
- 5 42. The host cell of claim 37 or 38, wherein the host cell is a bacterial cell.
43. A composition comprising the polypeptide molecule of claim 27 and a carrier.
44. A composition comprising the polypeptide molecule of claim 28 and a carrier.
- 10 45. An isolated antibody that specifically binds to the polypeptide molecule of claim 27.
46. The antibody of claim 45, wherein the antibody is a polyclonal antibody.
47. The antibody of claim 45, wherein the antibody is a monoclonal antibody.
48. A method for producing Gux1 polypeptide, the method comprising:  
incubating a host cell genetically engineered to express the polynucleotide molecule of claim  
27.
- 20 49. The method of claim 48, further comprising the step of:  
isolating the Gux1 polypeptide from the incubated host cells.
50. The method of claim 48, wherein the host cell is a plant cell.
- 25 51. The method of claim 48, wherein the host cell is a bacterial cell.
52. The method of claim 48, wherein the host cell is genetically engineered to express a  
selectable marker.
- 30

53. The method of claim 48, wherein the host cell further comprises a polynucleotide molecule encoding one or more polypeptide molecules selected from the glycoside hydrolase family of proteins.

5 54. The method of claim 53, wherein the glycoside hydrolase is a thermostable glycoside hydrolase.

55. A set of amplification primers for amplification of a polynucleotide molecule encoding Gux1, comprising:

10 two or more sequences comprising 9 or more contiguous nucleic acids derived from the polypeptide molecule of claim 27.

56. A probe for hybridizing to a polynucleotide encoding Gux1, comprising:  
a sequence of 9 or more contiguous nucleic acids derived from the polypeptide molecule of claim 27.

57. An assay method for the detection of a polynucleotide encoding Gux1, comprising:  
amplifying a nucleic acid sequence with a set of amplification primers comprising two or more sequences of 9 or more contiguous nucleic acids derived from the polypeptide molecule of claim 27; and  
20 correlating the amplified nucleic acid sequence with detected polypeptide encoding Gux1.

58. A method for assessing the carbohydrate degradation activity of Gux1 comprising:  
analyzing a carbohydrate degradation in the presence of Gux1 and a carbohydrate degradation  
25 in the absence of Gux1 on a substrate; and  
comparing the carbohydrate degradation in the presence of Gux1 with the carbohydrate degradation in the absence of Gux1.

59. A method for assessing the carbohydrate degradation activity of Gux1 in the presence of an  
30 agent of interest comprising:  
analyzing a carbohydrate degradation in the presence of Gux1 and a carbohydrate degradation in the presence of Gux1 and the agent of interest on a substrate exposed; and

comparing the carbohydrate degradation in the Gux1 treated substrate with the carbohydrate degradation in the Gux1 treated substrate in the presence of the agent of interest.

60. The method of claim 59, wherein an increase in carbohydrate degradation activity in the presence of the agent of interest demonstrates stimulation of Gux1 activity and wherein a decrease in carbohydrate degradation activity demonstrates inhibition of Gux1 activity.

61. The method of claim 58, wherein the carbohydrate is cellulose.

62. The method of claim 58 wherein the agent of interest is an antibody.

63. A method for reducing cellulose in a starting material, the method comprising:  
administering to the starting material an effective amount of a polypeptide molecule of claim 27.

64. The method of claim 63, further comprising administering a second polypeptide molecule selected from the glycoside hydrolase family of proteins.

65. The method of claim 63, wherein the polypeptide molecule of claim 27 is thermostable.

66. The method of claim 63, wherein the starting material is agricultural biomass.

67. The method of claim 63, wherein the starting material is municipal solid waste.

UNITED STATES PATENT AND TRADEMARK OFFICE  
DOCUMENT CLASSIFICATION BARCODE SHEET



# Abstract

6

Level - 2  
Version 1.1




**Abstract of the Disclosure**

The invention provides a thermal tolerant cellulase that is a member of the glycoside hydrolase family. The invention further discloses this cellulase as Gux1. Gux1 has been isolated and  
5 characterized from *Acidothermus cellulolyticus*. The invention further provides recombinant forms of the identified Gux1. Methods of making and using Gux1 polypeptides, including fusions, variants, and derivatives, are also disclosed.

UNITED STATES PATENT AND TRADEMARK OFFICE  
DOCUMENT CLASSIFICATION BARCODE SHEET



# Drawings



Level - 2  
Version 1.1

Fig. 1.

Domain structure of Gux1




5    ■ Signal    ▨ CBD<sub>1</sub>    ▨ CBD<sub>2</sub>    ▨ FN-III    ▨ Linker    □ Catalytic domain

10

15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995

FIG. 2

Diversity of glycoside hydrolase families



• glycoside hydrolase families

UNITED STATES PATENT AND TRADEMARK OFFICE  
DOCUMENT CLASSIFICATION BARCODE SHEET



# **Oath/Declaration, Small Entity, and Power of Attorney**

8

Level - 2  
Version 1.1

# COMBINED DECLARATION AND POWER OF ATTORNEY

As the below named inventor(s), I (we) hereby declare that:

My (Our) residence, post office address and citizenship(s) are as stated below next to my (our) name(s).

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

THERMAL TOLERANT EXOGLUCANASE FROM ACIDOTHERMUS CELLULOLYTICUS

the specification of which (check one)

☒ is attached hereto ☐ as filed on \_\_\_\_\_ as Serial No. \_\_\_\_\_  
and was amended \_\_\_\_\_

I (We) hereby state that I (we) have reviewed and understand the contents of the above-identified specification, including claims, as amended by any amendment referred to above.

I (We) acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I (We) hereby claim foreign priority benefits under Title 35, United States Code § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

## PRIOR FOREIGN APPLICATION(S)

Number	Country	Filed (Day/Month/Year)	Priority claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I (We) hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I (we) acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Serial No.	Filing Date	Status
		Pending

**POWER OF ATTORNEY:** As the named inventor(s), I (we) hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Names and Registration Nos.		Names and Registration Nos.
Paul J. White	30,346	
Ken Richardson	27,378	

<u>Send Correspondence to:</u>  Paul J. White Senior Counsel National Renewable Energy Laboratory 1617 Cole Boulevard Golden, CO 80401	<u>Direct Telephone Calls to:</u> (Name and Telephone Numbers)  Paul J. White  303/384-7575
--	--

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of joint inventor WILLIAM S. ADNEY  
Inventor's signature William S. Adney Date 26 July 01  
Residence Golden, Colorado Citizenship USA  
Post Office Address 13190 West 21<sup>st</sup> Avenue  
Golden, CO 80401


Full name of joint inventor SHI-YOU DING  
Inventor's signature Shiyou Ding Date 07/26/01  
Residence Golden, Colorado Citizenship China  
Post Office Address 26 South Halman Way, #1C  
Golden, CO 80401

Full name of joint inventor TODD B. VINZANT  
Inventor's signature Todd B. Vinzant Date 7/26/01  
Residence Golden, Colorado Citizenship USA  
Post Office Address 16601 West 15<sup>th</sup> Avenue  
Golden, CO 80401

Full name of joint inventor MICHAEL E. HIMMEL  
Inventor's signature Michael E. Himmel Date 7/26/01  
Residence Littleton, Colorado Citizenship USA  
Post Office Address 9202 W. Hialeah Place  
Littleton, CO 80123-2148

Full name of joint inventor STEPHEN R. DECKER  
Inventor's signature Stephen R. Decker Date 26 Jul 01  
Residence Berthoud, Colorado Citizenship USA  
Post Office Address 820 Greenwood Drive  
Berthoud, CO 80513

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of joint inventor SUZANNE LANTZ McCARTER  
Inventor's signature  Date 7/26/01  
Residence Denver, Colorado Citizenship USA  
Post Office Address 3072 West 39<sup>th</sup> Avenue  
Denver, CO 80211

Full name of joint inventor \_\_\_\_\_  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_  
Residence \_\_\_\_\_ Citizenship \_\_\_\_\_  
Post Office Address \_\_\_\_\_  
\_\_\_\_\_

Full name of joint inventor \_\_\_\_\_  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_  
Residence \_\_\_\_\_ Citizenship \_\_\_\_\_  
Post Office Address \_\_\_\_\_  
\_\_\_\_\_

Full name of joint inventor \_\_\_\_\_  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_  
Residence \_\_\_\_\_ Citizenship \_\_\_\_\_  
Post Office Address \_\_\_\_\_  
\_\_\_\_\_